GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
77.38
-0.22 (-0.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close77.60
Open77.40
Bid77.20 x 800
Ask77.69 x 3200
Day's Range77.04 - 77.89
52 Week Range64.27 - 89.54
Volume4,035,933
Avg. Volume7,230,258
Market Cap100.614B
Beta1.39
PE Ratio (TTM)29.43
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.28 (3.03%)
Ex-Dividend Date2018-06-14
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire2 days ago

    Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018

    Gilead Sciences, Inc. (GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes. At 5:00 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2018 and provide a general business update. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 8988927 to access the call.

  • Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy
    Business Wire6 days ago

    Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy

    Kite, a Gilead Company (GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy. In this position, Mr. Amoroso will have responsibility for Kite’s commercial organization including sales, marketing, market access, and healthcare provider and patient services.

  • ACCESSWIRE9 days ago

    Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio

    NEW YORK, NY / ACCESSWIRE / July 6, 2018 / U.S. markets rose Thursday on the strength of the technology sector, yet investors appear to be apprehensive as the U.S. prepare to place tariffs on Chinese goods. ...

  • European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
    Business Wire16 days ago

    European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy

    Kite, a Gilead Company (GILD), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s Marketing Authorization Application (MAA) for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel is a chimeric antigen receptor T cell (CAR T) therapy that modifies a patient’s own T cells to recognize and attack cancer cells and has the potential to induce complete responses (no detectable cancer) in a proportion of patients with aggressive forms of non-Hodgkin lymphoma (NHL).

  • Business Wire20 days ago

    European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

    Today’s decision makes BIC/FTC/TAF Gilead’s third FTC/TAF-based STR approved in the European Union in the past three years. “To help support the long-term health of people living with HIV, it is crucial to have regimens that deliver durable viral suppression with a high barrier to resistance,” said Professor Alan Winston, Professor of HIV and Genitourinary Medicine at Imperial College and Consultant Physician at St. Mary’s Hospital, London, UK.

  • GlobeNewswirelast month

    Consolidated Research: 2018 Summary Expectations for Encana, Netflix, Veon, The Walt Disney, Gilead Sciences, and Cloudera — Fundamental Analysis, Key Performance Indications

    NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Encana ...

  • ACCESSWIRElast month

    Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities

    On Wednesday, June 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Geron Corp. (NASDAQ: GERN), Gilead Sciences Inc. (NASDAQ: GILD), Global Blood Therapeutics Inc. (NASDAQ: GBT), and GlycoMimetics Inc. (NASDAQ: GLYC).

  • Business Wirelast month

    Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia

    Gilead Sciences, Inc. announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio

    NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Wall Street closed up Monday on the back of strong performances by the consumer discretionary and technology sectors. Investors appear to be focusing on positive ...

  • Business Wirelast month

    Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy

    Gilead Sciences, Inc. (GILD) today announced the promotion of Andrew Dickinson to Executive Vice President, Corporate Development and Strategy, with responsibility for Gilead’s corporate development, alliance management, competitive intelligence, and corporate strategy and planning functions, effective immediately. Mr. Dickinson will become a member of Gilead’s senior leadership team. The company also announced that Martin Silverstein, Executive Vice President, Strategy, has decided to leave Gilead at the end of August to return to the East Coast.

  • Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
    Business Wirelast month

    Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors

    Kite, a Gilead Company (GILD), today announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV.

  • Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
    Business Wirelast month

    Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting

    Kite, a Gilead Company , today announced new analyses from the ZUMA chimeric antigen receptor T cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago.

  • ACCESSWIRElast month

    Blog Exposure - Gilead Announces Approval of Epclusa in China

    LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want access to our free research report on Gilead Sciences, Inc. (NASDAQ: GILD), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=GILD as the Company's latest news hit the wire. On May 30, 2018, the Company announced that the China Drug Administration (CDA) has approved Epclusa® for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

  • GlobeNewswire2 months ago

    GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20 percent improvement score (ACR20). Filgotinib was generally well-tolerated in the EQUATOR trial, with no new safety signals observed and similar laboratory changes compared to those reported in previous trials with filgotinib in rheumatoid arthritis patients. "The data from the EQUATOR study are very impressive and indicate that filgotinib has the potential to have a significant effect on signs and symptoms of psoriatic arthritis, a condition where there is still a high unmet medical need," said Dr. Philip Mease, Director of Rheumatology Research, Swedish-Providence-St. Joseph Health Systems and Clinical Professor, University of Washington, Seattle, WA.

  • Business Wire2 months ago

    Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20 percent improvement score (ACR20). Filgotinib was generally well-tolerated in the EQUATOR trial, with no new safety signals observed and similar laboratory changes compared to those reported in previous trials with filgotinib in rheumatoid arthritis patients. “The data from the EQUATOR study are very impressive and indicate that filgotinib has the potential to have a significant effect on signs and symptoms of psoriatic arthritis, a condition where there is still a high unmet medical need,” said Dr. Philip Mease, Director of Rheumatology Research, Swedish-Providence-St. Joseph Health Systems and Clinical Professor, University of Washington, Seattle, WA.

  • Business Wire2 months ago

    Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13

    Gilead Sciences, Inc. today announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, and John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 13 at 8:40 a.m.

  • Business Wire2 months ago

    China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection

    Gilead Sciences, Inc. announced today that the China Drug Administration has approved Epclusa® for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection.

  • Business Wire2 months ago

    Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6

    Gilead Sciences, Inc. today announced that John F. Milligan, PhD, Gilead’s President and Chief Executive Officer; Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer; John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Development; and Andrew Cheng, Gilead’s Chief Medical Officer and Executive Vice President, will participate in a fireside chat ...

  • Business Wire2 months ago

    U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents

    Gilead Sciences, Inc. (GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. The safety and efficacy profile of Truvada for HIV prevention in uninfected adults, a strategy called pre-exposure prophylaxis (PrEP), is well established, and Truvada for PrEP was first approved for use in adults in 2012. The addition of the adolescent indication is based on a study in HIV-negative individuals 15 to 17 years of age.

  • Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
    Business Wire2 months ago

    Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

    Kite, a Gilead Company (GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp (SEGRO Park Amsterdam Airport) will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020. The facility will engineer and produce innovative cell therapies, including axicabtagene ciloleucel, a Chimeric Antigen Receptor T cell (CAR T) therapy that is currently under review by the European Medicines Agency and which is approved in the United States as Yescarta®.

  • Business Wire2 months ago

    Harish Manwani Joins Gilead Sciences’ Board of Directors

    Gilead Sciences, Inc.  announced today that Harish M. Manwani has been appointed to the company’s Board of Directors.

  • Business Wire2 months ago

    Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16

    Gilead Sciences, Inc. (GILD) today announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, and John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Wednesday, May 16 at 9:20 a.m. Pacific Time. The audio portion of the fireside chat will be accessible live through the company’s Investors page at www.gilead.com/investors.

  • ACCESSWIRE2 months ago

    Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space?

    Many investors missed the trend when Chinese pharmaceutical companies got hot. Many of these stocks are up 3-fold or more in the last year as Chinese biotechnology companies have played catch-up to U.S. companies in the booming cell therapy market. As a result, developers are turning to specialized contract development manufacturing organizations (CDMOs).

  • Business Wire2 months ago

    Gilead Sciences Announces Second Quarter 2018 Dividend

    Gilead Sciences, Inc. today announced that the company’s Board of Directors has declared a cash dividend of $0.57 per share of common stock for the second quarter of 2018.

  • Business Wire2 months ago

    Gilead Sciences Announces First Quarter 2018 Financial Results

    Gilead Sciences, Inc. announced today its results of operations for the first quarter ended March 31, 2018. The financial results that follow represent a year-over-year comparison of the first quarter 2018 to the first quarter 2017.